ABSTRACT
Objective: To analyze the relationship between monocyte to high-density lipoprotein cholesterol (HDL-C) ratio (MHR) in patients with ST-segment elevation myocardial infarction(STEMI) in order to explore the predictive value of MHR in thrombus burden level in STEMI patients. Methods: A total of 357 STEMI patients treated in our hospital from 2015-01 to 2016-12 were enrolled. Thrombus burden was confirmed by angiography and the patients were divided into 2 groups: Low thrombus burden group, n=156 and High thrombus burden group, n=201. MHR was compared between 2 groups; the predictive value of MHR in thrombus burden level was studied by multivariate Logistic regression analysis and ROC curve assessment. Results: MHR was higher in High thrombus burden group than that in Low thrombus burden group [M (Q1, Q3) 25.4 (13.5, 44.6) vs 16.0 (9.2, 22.1)], P<0.001; multivariate Logistic regression analysis indicated that MHR was the independent predictor for high thrombus burden occurrence (OR=1.067, 95％ CI 1.031-1.105), P<0.001; the area under ROC curve for MHR was 0.688 in STEMI patients. Conclusion: MHR was the independent predictor for high thrombus burden occurrence in STEMI patients.
ABSTRACT
<p><b>BACKGROUND</b>Atrial AutoCapture™ (ACap™) was a new technological development that confirmed atrial capture by analyzing evoked response (ER) with a new method - paced depolarization integral ER detection - and optimized energy output to changes in the stimulation threshold. The purpose of this study was to evaluate the clinical performance of ACap™ function.</p><p><b>METHODS</b>This was a prospective, observational, nonrandomized two-center study. Between November 2008 and August 2014, 102 patients were enrolled from two different institutions. Data were collected by case report forms at enrollment, hospital discharge, and in-office follow-ups scheduled at 1, 2, 3, 6, and 12 months postimplantation.</p><p><b>RESULTS</b>Ambulatory ACap™ function started to become available for 20.6% of patients at 1 day, then progressed to 30.4% at 7 days, 38.6% at 1 month, 41.6% at 2 months, 47.5% at 3 months, 53.5% at 6 months, and 63.4% at 1 year. The cause of the unsuccessful attempts to perform ACap™ threshold was ER/polarization <2:1. Availability for SD, BND, and HOCM indications had shown better results than AVB indication. For SD indication cases, feasibility was significantly better for SD with paroxysmal atrial fibrillation (pAF) than SD without pAF (78.4% vs. 35.0% at 1 year, n = 71, P< 0.001). At each stage of the clinical follow-ups, there had been a strict correlation between ACap™ measurements and those conducted manually with P 0.001 (n = 299).</p><p><b>CONCLUSIONS</b>It has been concluded that ACap™ function was safe and effective to confirm atrial threshold and reduce energy output automatically. ACap™ function is unavailable for some patients at early stages of the implantation; however, availability has been progressively increasing during follow-up.</p>